anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Risk Summary

Lactation studies have not been conducted with oral budesonide, including BUDESONIDE Capsules, and no information is available on the effects of the drug on the breastfed infant or the effects of the drug on milk production. One published study reports that budesonide is present in human milk following maternal inhalation of budesonide [see Data]. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for BUDESONIDE Capsules and any potential adverse effects on the breastfed infant from BUDESONIDE Capsules, or from the underlying maternal condition.

Data

One published study reports that budesonide is present in human milk following maternal inhalation of budesonide which resulted in infant doses approximately 0.3% to 1% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 0.4 and 0.5. Budesonide plasma concentrations were not detected and no adverse events were noted in the breastfed infants following maternal use of inhaled budesonide. The recommended daily dose of BUDESONIDE Capsules is higher (up to 9 mg daily) compared with inhaled budesonide (up to 800 mcg daily) given to mothers in the above described study. The maximum budesonide plasma concentration following a 9 mg daily dose (in both single-and repeated-dose pharmacokinetic studies) of oral budesonide is approximately 5 to 10 nmol/L which is up to 10 times higher than the 1 to 2 nmol/L for a 800 mcg daily dose of inhaled budesonide at steady state in the above inhalation study. Assuming the coefficient of extrapolation between the inhaled and oral doses is constant across all dose levels, at therapeutic doses of BUDESONIDE Capsules, budesonide exposure to the nursing child may be up to 10 times higher than that by budesonide inhalation.
A composite material for cosmetic purposes comprises water soluble native collagen and/or at least one water soluble collagen deriv. on a carrier. Pref. the compsn. includes a water soluble desamidocollagen cpd. Pref. at least part of the collagen (deriv.) is in foamed form.  The compsn. pref. also contains at least one structure-forming substance such as an aliginate and/or a polysaccharide and/ or a pectin and/or a xanthan.  The compsn. may also contain water soluble dyes or pigments, a cosmetically active agent such as plant and/or animal extracts or a vitamin, and liposomes, esp.  liposomes contg. water insoluble cosmetically active agents such as bisabolol. USE/ADVANTAGE - The materials are useful skin care preparations such as face masks which are soaked in water and applied with the collagen layer in contact with the skin.  In contrast to the crosslinked collagen derivs. used previously, the present materials allows saturation of the surface of the skin with active protein, which increases the water-binding capacity of the skin and thus improves the elasticity of the skin while the connective tissue becomes satd. with liq. and the circulation is promoted, which gives the skin a fresh appearance.
Patients in the CBSST group also attended up to 25 h of treatment but followed a manualized group therapy protocol (Granholm et al, 2005) using cognitive and behavioral therapy methods to increase patients' skills in symptom recognition, communication, problem solving, and relapse prevention. In both conditions, the facilitators interacted with the clients throughout small group (B4 patients) sessions: in the REM group, this mostly involved brief one-on-one discussions regarding task performance; in the CBSST condition, this interaction was in the context of the group milieu.
Tranexamic acid injection may cause seizures, including focal and generalized seizures. The most common setting for tranexamic acid-induced seizures has been during cardiovascular surgery (a setting in which tranexamic acid is not FDA-approved and which uses doses of up to 10-fold higher than the recommended human dose and in patients inadvertently given tranexamic acid into the neuraxial system). Tranexamic acid injection is not approved and not recommended for neuraxial administration. Consider dose reduction during surgery and dose adjustments for patients with clinical conditions such as renal dysfunction. Closely monitor the patient during surgery. Consider electroencephalogram (EEG) monitoring for patients with history of seizures or who experience myoclonic movements, twitching, or show evidence of focal seizures. Discontinue tranexamic acid injection if seizures occur.
Group A Streptococcus (GAS) is a versatile pathogen that targets human lymphoid, decidual, skin, and soft tissues. Recent advancements have shed light on its airborne transmission, lymphatic spread, and interactions with neuronal systems. GAS promotes severe inflammation through mechanisms involving inflammasomes, IL-1β, and T-cell hyperactivation. Additionally, it secretes factors that directly induce skin necrosis via Gasdermin activation and sustains survival and replication in human blood through sophisticated immune evasion strategies. These include lysis of erythrocytes, using red cell membranes for camouflage, resisting antimicrobial peptides, evading phagocytosis, escaping from neutrophil extracellular traps (NETs), inactivating chemokines, and cleaving targeted antibodies. GAS also employs molecular mimicry to traverse connective tissues undetected and exploits the host's fibrinolytic system, which contributes to its stealth and potential for causing autoimmune conditions after repeated infections. Secreted toxins disrupt host cell membranes, enhancing intracellular survival and directly activating nociceptor neurons to induce pain. Remarkably, GAS possesses mechanisms for precise genome editing to defend against phages, and its fibrinolytic capabilities have found applications in medicine. Immune responses to GAS are paradoxical: robust responses to its virulence factors correlate with more severe disease, whereas recurrent infections often show diminished immune reactions. This review focuses on the multifaceted virulence of GAS and introduces novel concepts in understanding its pathogenicity.
Hospitals are not consistently patient centered, contributing to worse outcomes and a sense of loss of control. Prior interventions that promote patient-centered care focused on provider and hospital factors vs. engaging patients directly. No project to date has capitalized on digital health technology to engage families in shared decision-making and patient engagement. The goal of the proposed randomized controlled trial is to test the impact of an evidence-based educational module delivered using an interactive patient-facing IT platform, on measures of patient engagement and shared decision-making. The platform was developed for the UCSF Benioff Children's Hospital by OneView, Inc. and includes an educational module that promotes shared decision-making through orientation to the hospital and evidence-based teaching on engaging with providers. This study will provide pilot data for a large-scale trial measuring the impact of the system on patient engagement. The investigators will start by finalizing the educational module and adding randomization for the trial (Aim 1). The investigators will then complete iterative user testing in the live system through measurement of educational module views and usability feedback interviews with 20 end users (Aim 2). The investigators will then conduct a randomized controlled trial to test the impact of the educational module on existing measures of patient engagement (Aim 3). Our hypothesis is that parents who receive the educational module will have higher scores on shared decision-making, patient activation and overall patient experience. The eligible study population is all pediatric and newborn inpatients and their caregivers from June 2015 - August 2015. The investigators anticipate needing a sample size of 100, 50 in each arm. This pilot will generate key information on the platform's feasibility and acceptability and initial data on effect sizes to power future large-scale grants.
In some embodiments, techniques for generating a user interface for summarizing care trend information for multiple patients are provided. For each patient of a plurality of patients, treatment information is collected for the patient from an electronic health record system. The treatment information reflects at least one of a patient acuity, a patient clinical problem, and a clinical change in the patient. An overview presentation of the plurality of patients is generated. The overview presentation includes summarized information for each patient of the plurality of patients. The overview presentation is presented to a user. The overview presentation allows a user to prioritize care for the plurality of patients in a way that is superior to browsing individual patient records within the electronic health record system.
Provided are a composition and method for vaginal therapy. The composition includes a delivery compound and a pharmaceutically active agent dispersed in the delivery compound. The pharmaceutically active agent includes a centrally acting muscle relaxant. The method for vaginal therapy includes preparing a composition including a pharmaceutically active agent dispersed in a delivery compound, and administering the composition intravaginally. The pharmaceutically active agent includes a muscle relaxant. Another method includes administering the composition extravaginally and then administering the composition intravaginally.
BACKGROUND: Vacuum-assisted closure (VAC) temporization is a technique associated with high local control rates used in myxofibrosarcoma. We sought to compare the costs and postoperative outcomes of VAC temporization and single-stage (SS) excision/reconstruction.
METHODS: We conducted a retrospective analysis of patients with myxofibrosarcoma surgically treated at our institution between 2000 and 2022. Variables of interest included total, direct, and indirect costs for initial episode of care, 90 days and 1 year after initial admission, and postoperative outcomes. Costs were compared between the VAC temporization and SS groups.
RESULTS: After matching, 13 patients in the SS group and 23 in the VAC group were analyzed. We found no difference in median and mean total inpatient costs, between the VAC temporization and SS group. While total 90-day and 1-year costs were higher in the VAC group compared to the SS group, mean costs were similar. There were no differences in postoperative complications between groups. A subanalysis of the entire cohort (n = 139) revealed lower local recurrence and overall death rates in the VAC temporization group.
CONCLUSION: VAC temporization had similar inpatient costs and postoperative outcomes to SS excision/reconstruction. While median 90-day and 1-year costs were higher in the VAC group, mean costs did not differ.
Selective beta-3 receptor agonist oral medication approved for the treatment of urgency urinary incontinence including mirabegron or vibegron. Usual clinical care standards will be used for prescribing and dosing changes. For mirabegron, dosages are 25 mg and 50 mg as clinically indicated. For vibegron, dosage is 75 mg daily by mouth as clinically indicated.
Venous thromboembolism (VTE) refers to abnormal coagulation of blood in veins, resulting in complete or incomplete occlusion of the blood vessels. Patients with liver cirrhosis are prone to blood clots. However, relationship between NDUFB2 and UQCRH and VTE is not clear. GSE19151 and GSE48000 profiles for venous thromboembolism were downloaded from gene expression omnibus (GEO) generated using GPL571 and GPL10558. Multiple datasets were merged and batched. The differentially expressed genes (DEGs) were screened and weighted gene co-expression network analysis (WGCNA) was performed. The construction and analysis of protein-protein interaction (PPI) network, functional enrichment analysis, Gene Set Enrichment Analysis (GSEA) were conducted. Gene expression heat map was drawn. Comparative toxicogenomics database (CTD) analysis were performed to find disease most related to the core genes. Western blotting (WB) experiments were further verified. TargetScan screened miRNAs that regulated central DEGs. 129 DEGs were identified. According to gene ontology (GO), DEGs were mainly enriched in mRNA metabolism, oxidative phosphorylation, nucleic acid binding and enzyme binding. The Kyoto Encyclopedia of Gene and Genome (KEGG) analysis showed that target cells were mainly enriched in ribosomes and oxidative phosphorylation. The intersection of enrichment items and GOKEGG enrichment items of DEGs is mainly enriched in oxidative phosphorylation, myocardial contraction and ribosome. In the metascape enrichment project, dna template transcription, cell stress response regulation and proton transport across the membrane can be seen in the GO enrichment project. The PPI network obtained 10 core genes (COX7C, NDUFB2, ATP5O, NDUFA4, NDUFAB1, ATP5C1, ATP5L, NDUFA7, NDUFA6, UQCRH). Gene expression heat map showed that 5 core genes (NDUFAB1, NDUFB2, UQCRH, COX7C, NDUFA4) were highly expressed in venous thromboembolism samples, and lowly expression in normal tissue samples, and 2 core genes (NDUFA7, NDUFA6) were lowly expressed in venous thromboembolism samples. CTD analysis showed that 5 genes (NDUFAB1, NDUFB2, UQCRH, COX7C, NDUFA4) were found to be associated with obesity, necrosis, inflammation and hepatomegaly. The result of WB showed that expression level of NDUFB2 and UQCR in venous thromboembolism was higher than that in control group. NDUFB2 and UQCRH are highly expressed in venous thromboembolism with liver cirrhosis, making them potential molecular targets for early diagnosis and precise treatment.
NOT FOR OPHTHALMIC USE. NOT FOR INJECTION.

CIPRO® HC OTIC should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones. Serious acute hypersensitivity reactions may require immediate emergency treatment. The dropper cap contains natural rubber (latex) which may cause severe allergic reactions.
The invention discloses a psoriasis smudging stick and a manufacturing and use method thereof. The smudging stick is prepared from 5-15 parts of chaulmoogratree seeds, 7-16 parts of capsicum annuum, 8-15 parts of camphor, 6-20 parts of fructus cnidii, 5-19 parts of cortex moutan, 7-13 parts of radix sophorae flavescentis, 6-18 parts of calomel, 8-21 parts of veratrum nigrum, 8-15 parts of realgar, 4-18 parts of borneol and 300-900 parts of moxa floss. The formula is prepared through pure traditional Chinese medicine, and the smudging stick is free of toxic and side effects and is safe and convenient. Different from external application medicine always containing various hormones, and internal application medicine of Western medicine, the smudging stick solves the problem that traditional Chinese medicine is bitter and difficult to take, and harm of oral administration of traditional Chinese medicine or Western medicine to livers, stomachs and other organs of human bodies can be reduced to the largest extent. In the smudging combustion process of the smudging stick, matter generated by the smudging stick is absorbed by skin and can take effect immediately, and the medicine effect is faster compared with that of oral medicines in traditional Chinese medicine and Western medicine. Besides, the psoriasis smudging stick has the effects of clearing away heat and cooling the blood, dispelling wind and eliminating dampness, relieving itching and clearing away toxin, activating blood circulation to remove blood stasis and eliminating measles and removing stasis, and pain, caused by pruritus, of patients can be quickly relieved.
<P>PROBLEM TO BE SOLVED: To provide a protein which is a protein of a rice origin or rice material brewed food origin and excellent in the lipid metabolism ameliorating effectiveness.  <P>SOLUTION: The protein is a protein of a rice origin or a rice material brewed food origin and is characterized by having the following physicochemical properties from (a) to (c) in the followings. (a) The protein has insolubility or poor solubility to water, an organic solvent, a salt aqueous solution, and an alkali solution. (b) The protein has poor hydrolyzability to cellulase, hemicellulase, mannanase, and protease, and is indigestible to pepsin and pancreatin. (c) The protein has a molecular weight in the range of 8 kDa to 15 kDa.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Endothelial dysfunction is important in the pathology of pulmonary hypertension, and circulating endothelial progenitor cells (EPCs) have been studied to evaluate endothelial dysfunction. In patients with chronic thromboembolic pulmonary hypertension (CTEPH), riociguat reportedly increases the number of circulating EPCs. However, the relationship between EPC numbers at baseline and changes in clinical parameters after riociguat administration has not been fully elucidated. Here, we evaluated 27 treatment-naïve patients with CTEPH and analyzed the relationships between EPC number at diagnosis and clinical variables (age, hemodynamics, atrial blood gas parameters, brain natriuretic peptide, and exercise tolerance) before and after riociguat initiation. EPCs were defined as CD45dim CD34+ CD133+ cells and measured by flow cytometry. A low number of circulating EPCs at diagnosis was significantly correlated with increased reductions in mean pulmonary arterial pressure (mPAP) (correlation coefficient = 0.535, P = 0.004) and right atrial pressure (correlation coefficient = 0.618, P = 0.001) upon riociguat treatment. We then divided the study population into two groups according to the mPAP change: a weak-response group (a decrease in mPAP of 4 mmHg or less) and a strong-response group (a decrease in mPAP of more than 4 mmHg). The number of EPCs at diagnosis was significantly lower in the strong-response group than in the weak-response group (P = 0.022), but there were no significant differences in other clinical variables or in medication profiles. In conclusion, circulating EPC numbers could be a potential predictor of the therapeutic effect of riociguat in CTEPH patients.
The threat of zoonotic malaria remains largely overlooked in India, particularly in regions such as the Western Ghats (WG), a biodiversity hotspot. The WG has diverse species of non-human primates that serve as reservoir hosts for simian malaria parasites. The presence of the Leucosphyrus group of mosquitoes and other vectors of human malaria makes WG vulnerable to the risk of parasite spillover. Natural and anthropogenic factors have contributed to rampant changes in the WG landscape, leading to increased interaction with the sylvatic hosts and vectors. The simian host-human-vector-environment interactions govern the transmission dynamics of zoonotic malaria; however, our knowledge of these interlinkages, encompassing the effect of anthropogenic disruptions in the WG is limited. The impending threat of zoonotic malaria in India could decelerate progress toward malaria elimination, warranting a comprehensive and systematic investigation of disease dynamics in the WG.
PROBLEM TO BE SOLVED: To provide a medicament for the treatment of constipation-predominant irritable bowel syndrome.SOLUTION: A medicament for the treatment of constipation-predominant irritable bowel syndrome (c-IBS) contains an extract or latex isolated from Croton spp. or Calophyllum spp. Further, a medicament for the treatment of constipation-predominant irritable bowel syndrome (c-IBS) contains a polymeric proanthocyanidin composition isolated from Croton spp. or Calophyllum spp. Treatment of c-IBS includes the treatment of the constipation component of c-IBS as well as the pain and abdominal discomfort associated with c-IBS. The polymeric proanthocyanidin composition contains at least one monomer selected from the group consisting of catechin, epicatechin, gallocatechin and epigallocatechin, and is crofelemer. The medicament for the treatment is formulated for oral administration in an amount of between 250 mg per day and 4000 mg per day.
Mutations in the leucine-rich repeat kinase (LRRK2) gene cause late-onset autosomal dominant Parkinson's disease (PD) with pleiomorphic pathology. Previously, we and others found that expression of mutant LRRK2 causes neuronal degeneration in cell culture. Here we used the GAL4/UAS system to generate transgenic  Drosophila  expressing either wild-type (WT1) human LRRK2 or LRRK2-G2019S, the most common mutation associated with PD. Expression of either WT1 human LRRK2 or LRRK2-G2019S in the photoreceptor cells caused retinal degeneration. Expression of WT1 LRRK2 or LRRK2-G2019S in neurons produced adult-onset selective loss of dopaminergic neurons, locomotor dysfunction, and early mortality. Expression of mutant G2019S-LRRK2 caused a more severe parkinsonism-like phenotype than expression of equivalent levels of WT1 LRRK2. Treatment with L-DOPA improved mutant LRRK2-induced locomotor impairment but did not prevent the loss of tyrosine hydroxylase (TH)-positive neurons. To our knowledge, this is the first in vivo “gain-of-function” model which recapitulates several key features of LRRK2-linked human parkinsonism. These flies may provide a useful model for studying LRRK2-linked pathogenesis and for future therapeutic screens for PD intervention.
PURPOSE: To compare ocular and anesthesia-related complications in a cohort of patients having undergone either delayed sequential bilateral cataract surgery (DSBCS) or immediate sequential bilateral cataract surgery (ISBCS).
METHODS: The medical records of children who underwent bilateral cataract surgery at our institution between 2012 and 2021were reviewed retrospectively. Included patients were 0-24 months of age, aphakic, and followed for at least 1 year after surgery.
RESULTS: A total of 56 children were included: 23 underwent ISBCS; 33, DSBCS. Mean age at surgery was 2.6 ± 2.5 months for ISBCS patients and 2.8 ± 3.0 months for DSBCS patients (P = 0.752). Association with systemic diseases was more common in the ISBCS group. The mean anesthesia time per child was shorter in the ISBCS group (P < 0.001), although the mean total procedure time was similar in both groups. The rate of intraoperative anesthesia-related complications and intraocular complications was similar in both groups. There were no cases of endophthalmitis. The mean number of additional surgical interventions per child and the mean number of follow-up visits within 1 year were similar between groups. Children in the ISBCS group required fewer nights of hospital admission (P < 0.001).
CONCLUSIONS: ISBCS in children in this series did not lead to an increased incidence of ocular or anesthesia-related complications compared with DSBCS. ISBCS avoids repeated anesthesia and shortens the total time that the child is under anesthesia.
The present invention relates to a traditional Chinese medicine composition which is an edible health-care product prepared from the raw material of aloe. The traditional Chinese medicine composition can be eaten by smokers all the year for lightening physical harm to the smokers caused by smoking. The basic raw material prescription of the traditional Chinese medicine composition comprises 50% to 80% of fresh aloe leaf, 2% to 20% of dogbane leaf, 2% to 20% of heartleaf houttuynia herb, 1% to 2% of platycodon root, 1% to 2% of liquorice and 8% to 14% of honey. Glue liquid is extracted from aloe and is mixed with extracts of other traditional Chinese medicine ingredients; then, a preservative and an antioxidant are added, and the composition of the present invention can be obtained. The traditional Chinese medicine composition can effectively reduce the toxicity of nicotine and tar in the bodies of the smokers, and enhance the function of resisting radiation damage and the immunity of a body. The traditional Chinese medicine composition is an ideal raw material for producing a health-care product for the smokers.